{"id":"placebo-narlaprevir","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL1255891","moleculeType":"Small molecule","molecularWeight":"707.98"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Narlaprevir works by inhibiting the NS3/4A protease enzyme, which is essential for the replication of the HCV virus. This leads to a reduction in viral load and an improvement in liver function. Narlaprevir is often used in combination with other antiviral medications to achieve optimal treatment outcomes.","oneSentence":"Narlaprevir is a protease inhibitor used to treat hepatitis C virus (HCV) infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:31.265Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus (HCV) infection"},{"name":"HCV genotype 1 infection"}]},"trialDetails":[{"nctId":"NCT03833362","phase":"PHASE3","title":"Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2014-05-07","conditions":"Hepatitis C","enrollment":420},{"nctId":"NCT01081158","phase":"PHASE1","title":"Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Genotype 1 (Protocol No. P04695)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Hepatitis C, Chronic","enrollment":41}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo Narlaprevir","genericName":"Placebo Narlaprevir","companyName":"R-Pharm","companyId":"r-pharm","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Narlaprevir is a protease inhibitor used to treat hepatitis C virus (HCV) infection. Used for Chronic hepatitis C virus (HCV) infection, HCV genotype 1 infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}